This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Sarah DeVos, PhD
Director and Principal Scientist at Denali Therapeutics


Dr. Sarah DeVos, Ph.D, is currently a Director and Principal Scientist at Denali Therapeutics Inc focusing on neurodegenerative disease drug discovery and development. She co-leads the Preclinical Translational Sciences function and manages preclinical model development and biomarker in vivo assessments across Denali’s large molecule portfolio. Additionally, Dr. DeVos is the Platform Lead for the oligonucleotide transport vehicle (OTV) programs at Denali. In this role, she liaises with multiple cross-functional teams, including protein and chemical engineering, pharmacology sciences, biomarker sciences, and safety sciences. She also serves on the joint scientific committee collaboration with Secarna Pharmaceuticals for ASO bioinformatics and lead identification.

Over the course of her career, Dr. DeVos has worked closely with peers in both academia and industry to better understand the druggability of neurodgenerative disorders, primarily focusing on Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD). She has published numerous papers and patents in the neurodgenerative and oligonucleotide space, with dedicated passion towards merging these two areas.

Prior to starting her career in industry at Denali Therapeutics, Dr. DeVos received her Ph.D. in Neuroscience from Washington University in St Louis as a member in Dr. Timothy Miller’s Lab and her B.S. degree in Neuroscience from Central Michigan University. After receiving her Ph.D, she went on to perform her postdoctoral research in the Department of Neurology at Massachusetts General Hospital in Dr. Bradley Hyman’s Lab.

Agenda Sessions

  • Targeting Transferrin Receptor to Enable Uniform Biodistribution of Antisense Oligonucleotides Using a Systemic Dose Route